Literature DB >> 33838082

Targeted Degradation of PARP14 Using a Heterobifunctional Small Molecule.

Tim J Wigle1, Yue Ren1, Jennifer R Molina1, Danielle J Blackwell1, Laurie B Schenkel1, Kerren K Swinger1, Kristy Kuplast-Barr1, Christina R Majer1, W David Church1, Alvin Z Lu1, Jason Mo1, Ryan Abo1, Anne Cheung1, Bryan W Dorsey1, Mario Niepel1, Nicholas R Perl1, Melissa M Vasbinder1, Heike Keilhack1, Kevin W Kuntz1.   

Abstract

PARP14 is an interferon-stimulated gene that is overexpressed in multiple tumor types, influencing pro-tumor macrophage polarization as well as suppressing the antitumor inflammation response by modulating IFN-γ and IL-4 signaling. PARP14 is a 203 kDa protein that possesses a catalytic domain responsible for the transfer of mono-ADP-ribose to its substrates. PARP14 also contains three macrodomains and a WWE domain which are binding modules for mono-ADP-ribose and poly-ADP-ribose, respectively, in addition to two RNA recognition motifs. Catalytic inhibitors of PARP14 have been shown to reverse IL-4 driven pro-tumor gene expression in macrophages, however it is not clear what roles the non-enzymatic biomolecular recognition motifs play in PARP14-driven immunology and inflammation. To further understand this, we have discovered a heterobifunctional small molecule designed based on a catalytic inhibitor of PARP14 that binds in the enzyme's NAD+ -binding site and recruits cereblon to ubiquitinate it and selectively target it for degradation.
© 2021 Wiley-VCH GmbH.

Entities:  

Keywords:  ADP-ribosylation; IL-4; PARP14; degrade; macrophages

Mesh:

Substances:

Year:  2021        PMID: 33838082     DOI: 10.1002/cbic.202100047

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  3 in total

Review 1.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

Review 2.  Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules.

Authors:  Maria Giulia Nizi; Mirko M Maksimainen; Lari Lehtiö; Oriana Tabarrini
Journal:  J Med Chem       Date:  2022-05-24       Impact factor: 8.039

3.  ADP-ribosyltransferases, an update on function and nomenclature.

Authors:  Bernhard Lüscher; Ivan Ahel; Matthias Altmeyer; Alan Ashworth; Peter Bai; Paul Chang; Michael Cohen; Daniela Corda; Françoise Dantzer; Matthew D Daugherty; Ted M Dawson; Valina L Dawson; Sebastian Deindl; Anthony R Fehr; Karla L H Feijs; Dmitri V Filippov; Jean-Philippe Gagné; Giovanna Grimaldi; Sebastian Guettler; Nicolas C Hoch; Michael O Hottiger; Patricia Korn; W Lee Kraus; Andreas Ladurner; Lari Lehtiö; Anthony K L Leung; Christopher J Lord; Aswin Mangerich; Ivan Matic; Jason Matthews; George-Lucian Moldovan; Joel Moss; Gioacchino Natoli; Michael L Nielsen; Mario Niepel; Friedrich Nolte; John Pascal; Bryce M Paschal; Krzysztof Pawłowski; Guy G Poirier; Susan Smith; Gyula Timinszky; Zhao-Qi Wang; José Yélamos; Xiaochun Yu; Roko Zaja; Mathias Ziegler
Journal:  FEBS J       Date:  2021-07-29       Impact factor: 5.622

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.